Pulsed Electromagnetic Fields for Clinical Applications: 1st Edition (Hardback) book cover

Pulsed Electromagnetic Fields for Clinical Applications

1st Edition

Edited by James Ryaby, Phd, Marko Markov

CRC Press

300 pages | 25 B/W Illus.

Purchasing Options:$ = USD
Hardback: 9780367179717
pub: 2020-03-01
SAVE ~$29.99
Available for pre-order. Item will ship after 1st March 2020

FREE Standard Shipping!


This book presents the historical development, the state of art and the future of the application of PEMF for treatment of various medical problems, including initiating various healing processes from delayed fractures and pain relief, to multiple sclerosis, and Parkinson's disease. In perspective, this modality provides a practical, exogenous method for inducing cell and tissue modification attempted to return the injured tissues to their normal physiological status. The book will review the current state of equipment for REM, as well as highlight worldwide therapeutic achievements.

Table of Contents

1. Historical Development of Research of Pulsed Electromagnetic Field in Biology and Medicine. 2. Pulsed Electromagnetic Fields from Signaling to Healing. 3. Types of Signals and Devices. 4. Review of Scientific Evidence for Successful Clinical Applications. 5. In Search of Mechanisms of Action. 6. Cooperation Between Engineers, Biologists and Clinicians. 7. Necessity of Proper Biophysical Dosimetry in Laboratory and Medical Facilities. 8. Electroporation Methods as Therapeutic Modalities – Today and Tomorrow.

About the Editors

Marko S. Markov received his BS, MS and PhD from Sofia University, Bulgaria. He has been professor

and chairman of the Department of Biophysics and Radiobiology of Safi university for 22 years. He

has been an invited professor and lecturer in a number of European and American academic and

industry research centers.

Jim Ryaby, PhD joined Orthofix as Chief Scientific Officer in July 2013 after serving as a

consultant. Before joining the Company, he served as Vice President of Research and Clinical

Affairs for musculoskeletal applications at Mesoblast. Dr. Ryaby has also held th position of

Senior Vice President of Research and Clinical Affairs and Chief Scientific Officer at OrthoLogic

Corp in Tempe, AZ. where he led the development of the CMF technology for spine fusion and

nonunions and the TP508 peptide therapeutic development program in orthopedic and diabetic ulcer

applications. Additionally, he has served as Adjunct Professor of Bioengineering at Arizona State

University. Dr. Ryaby received his PhD degree in cellular and molecular biology from the Mt. Sinai School of Medicine, New York.

Subject Categories

BISAC Subject Codes/Headings: